Gilead 3Q Revenues: $7.5 billion (-10%) 3Q Earnings: $3.3 billion (-28%) YTD Revenues: $23.1 billion (-4%) YTD Earnings: $10.4 billion (-23%) Comments: HIV and other antiviral product sales were $3.5 billion, up 21% primarily due to continued uptake of tenofovir alafenamide (TAF) based products, Genvoya, Descovy, and Odefsey. HCV product sales, which consist of Harvoni, Sovaldi, and Epclusa, were $3.3 billion down 31% due to lower sales of Harvoni and Sovaldi, partially offset by ...